TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to…

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing is pleased to…

TORONTO, April 17, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share capital (the "Common Shares")…

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that…

Psyence Group settles Debt for Shares Psyence Group settles Debt for Shares